A Biology Modality MCP review of EBAG9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CX3CR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CRLF3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CRLF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A 2026 BD opportunity scan of OrganoTherapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Allogenetics GmbH, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Alphina Therapeutics, Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Oak Hill Bio Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Orbis Medicines ApS, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Navega Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Noa Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Constantiam Biosciences, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.